Acne
Actinic Keratosis
Aesthetics
Alopecia
Atopic Dermatitis
Buy-and-Bill
COVID-19
Case-Based Roundtable
Chronic Hand Eczema
Drug Watch
Eczema
General Dermatology
Hidradenitis Suppurativa
Melasma
NP and PA
Pediatric Dermatology
Pigmentary Disorders
Practice Management
Precision Medicine and Biologics
Prurigo Nodularis
Psoriasis
Psoriatic Arthritis
Rare Disease
Rosacea
Skin Cancer
Vitiligo
Wound Care

Expert Insights on the Use of Oral JAK Inhibitors for Atopic Dermatitis: Raising the Bar for Standard of Care : Episode 1

Opinion

Video

July 20, 2023

JAK Inhibitor Overview and Relevance to AD

Author(s):

Christopher G. Bunick, MD, PhD,Ruth Ann Vleugels, MD, MPH, MBA

Christopher Bunick, MD, PhD, and Ruth Ann Vleugels, MD, MPD, MBA, discuss the method of action for Janus Kinase (JAK) inhibitors and the pathology of atopic dermatitis (AD).

Video Player is loading.

Current Time 0:00

Duration 8:17

Loaded: 0%

Stream Type LIVE

Remaining Time 8:17

Now Viewing

EP: 1.JAK Inhibitor Overview and Relevance to AD

EP: 2.Comparing Current Treatment Agents for AD

EP: 3.Clinical Experience With JAK Inhibitor in AD

EP: 4.Experts Present Background on Long-Term Safety Study of Upadacitinib for AD

EP: 5.Experts on Results of Long-Term Safety Study of Upadacitinib for AD

EP: 6.Conclusions of Study on Long-Term Safety Study of Upadacitinib for AD

EP: 7.Assessing Risk Factors of Oral JAK Inhibitors and Traditional Agents

EP: 8.Experts Present Background on JAK Inhibitor vs Systemic Immunosuppressant Safety Study

EP: 9.Experts on Results of JAK Inhibitor vs Systemic Immunosuppressant Safety Study

EP: 10.Visualizing Safety Rates: Drug Events, Disease Baseline, and General Population Baseline

EP: 11.Box Warning and JAK Inhibitor

EP: 12.JAK Inhibitor Selectivity

EP: 13.Conclusions of JAK Inhibitor vs Systemic Immunosuppressant Safety Study

EP: 14.Evolving the Standard of Care for AD: Safety and Treatment Response

EP: 15.Transitioning Patients from Traditional Immunosuppressive Agents to JAK Inhibitor

EP: 16.AD Endotypes and Outcomes

EP: 17.Final Thoughts on JAK Inhibitor for AD

Related Videos

Balancing Effective AD Symptom Control with Long-Term Safety in New Therapies

Key Considerations for Evaluating Ruxolitinib Cream as a Treatment for Young Children

Supporting Caregivers in Successful Long-Term Atopic Dermatitis Management: The Role of Dermatologists

Challenges and Emerging Solutions in Treatment for Age Groups: Addressing Disease Control, Safety, and Usability

Challenges and Unmet Needs in Treating Pediatric Atopic Dermatitis

New Biomarker Test Revolutionizes Inflammatory Skin Disease Diagnosis

Reviewing 3 Key Lebrikizumab Abstracts From AAD 2025

Future Directions for Pediatric Atopic Dermatitis Management and Research

New Systemic Therapies for Pediatric Atopic Dermatitis: Nemolizumab and Oral JAK Inhibitors

Addressing Disparities in Inflammatory Skin Diseases in Darker Skin Tones